Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00349180
Status:
COMPLETED
Last Update Posted:
2009-03-27
First Post:
2006-07-04
Brief Title:
Total Hip Replacement Study With XRP4563 Enoxaparin Sodium
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Multicenter Randomized Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin SodiumRP5456320mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is performed to confirm the optimal dose for THR total hip replacement
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None